$588 Million is the total value of BVF INC/IL's 30 reported holdings in Q1 2017. The portfolio turnover from Q4 2016 to Q1 2017 was 31.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BPMC | Sell | BLUEPRINT MEDICINES CORP | $84,070,000 | -7.9% | 2,102,280 | -35.4% | 14.30% | -22.1% |
| CCXI | Buy | CHEMOCENTRYX INC | $58,171,000 | +0.8% | 7,990,572 | +2.5% | 9.89% | -14.7% |
| CYTK | Sell | CYTOKINETICS INC | $54,752,000 | -7.1% | 4,260,836 | -12.2% | 9.31% | -21.4% |
| ANAB | New | ANAPTYSBIO INC | $48,246,000 | – | 1,738,600 | +100.0% | 8.21% | – |
| CNCE | Sell | CONCERT PHARMACEUTICALS INC | $39,863,000 | +48.1% | 2,336,609 | -10.7% | 6.78% | +25.3% |
| CTMX | Buy | CYTOMX THERAPEUTICS INC | $31,167,000 | +411.2% | 1,804,675 | +225.3% | 5.30% | +332.7% |
| FWP | FORWARD PHARMA A/Ssponsored adr | $29,908,000 | +43.6% | 1,387,853 | 0.0% | 5.09% | +21.6% | |
| INFI | Buy | INFINITY PHARMACEUTICALS INC | $25,408,000 | +139.4% | 7,866,108 | +0.1% | 4.32% | +102.7% |
| ARRY | Sell | ARRAY BIOPHARMA INC | $24,702,000 | -43.6% | 2,763,086 | -44.6% | 4.20% | -52.3% |
| CTIC | New | CTI BIOPHARMA CORP | $18,815,000 | – | 4,479,691 | +100.0% | 3.20% | – |
| BLRX | New | BIOLINERX LTD SPONSOREDsponsored adr | $16,809,000 | – | 17,500,000 | +100.0% | 2.86% | – |
| OMED | ONCOMED PHARMACEUTICALS INC | $16,214,000 | +19.5% | 1,760,489 | 0.0% | 2.76% | +1.1% | |
| GLYC | GLYCOMIMETICS INC | $15,347,000 | -11.0% | 2,826,282 | 0.0% | 2.61% | -24.7% | |
| ACHN | Buy | ACHILLION PHARMACEUTICALS INC COM | $13,832,000 | +38.2% | 3,285,400 | +35.6% | 2.35% | +17.0% |
| LOXO | New | LOXO ONCOLOGY INC | $13,466,000 | – | 320,000 | +100.0% | 2.29% | – |
| CASC | CASCADIAN THERAPEUTICS INC | $12,972,000 | -3.9% | 3,133,224 | 0.0% | 2.21% | -18.7% | |
| XENE | Sell | XENON PHARMACEUTICALS INC | $11,799,000 | -49.7% | 2,949,794 | -3.1% | 2.01% | -57.4% |
| XOMA | Buy | XOMA CORP DEL | $10,685,000 | +736.1% | 1,502,800 | +396.3% | 1.82% | +607.0% |
| FATE | Sell | FATE THERAPEUTICS INC | $8,851,000 | -6.2% | 1,945,245 | -48.3% | 1.50% | -20.6% |
| IMDZ | Sell | IMMUNE DESIGN CORP | $8,391,000 | +15.6% | 1,233,976 | -6.5% | 1.43% | -2.2% |
| ARQL | ARQULE INC | $7,844,000 | -15.9% | 7,400,128 | 0.0% | 1.33% | -28.8% | |
| SNSS | Buy | SUNESIS PHARMACEUTICALS INC | $6,315,000 | +25.2% | 1,540,323 | +10.6% | 1.07% | +6.0% |
| OREXIGEN THERAPEUTICS INCnote 2.750% | $5,475,000 | +82.5% | 10,000,000 | 0.0% | 0.93% | +54.4% | ||
| NVLS | NIVALIS THERAPEUTICS INC | $5,444,000 | +30.4% | 1,864,474 | 0.0% | 0.93% | +10.4% | |
| GTXI | GTX INC DEL | $5,387,000 | -8.0% | 1,108,433 | 0.0% | 0.92% | -22.1% | |
| PIRS | Buy | PIERIS PHARMACEUTICALS INC | $4,984,000 | +91.3% | 1,917,033 | +3.4% | 0.85% | +61.8% |
| ANTH | Buy | ANTHERA PHARMACEUTICALS INC | $3,426,000 | +8465.0% | 8,052,073 | +12826.3% | 0.58% | +7187.5% |
| OREXQ | OREXIGEN THERAPEUTICS INC | $2,528,000 | +97.7% | 734,976 | 0.0% | 0.43% | +67.3% | |
| PTIE | PAIN THERAPEUTICS INC | $2,035,000 | +56.7% | 2,278,552 | 0.0% | 0.35% | +32.6% | |
| RGLS | New | REGULUS THERAPEUTICS INC | $1,028,000 | – | 623,000 | +100.0% | 0.18% | – |
| ADRO | Exit | ADURO BIOTECH INC | $0 | – | -745,886 | -100.0% | -1.71% | – |
| ESPR | Exit | ESPERION THERAPEUTICS INC NE | $0 | – | -712,770 | -100.0% | -1.79% | – |
| CLCD | Exit | COLUCID PHARMACEUTICALS INC | $0 | – | -484,335 | -100.0% | -3.54% | – |
| CTIC | Exit | CTI BIOPHARMA CORP | $0 | – | -44,796,940 | -100.0% | -3.63% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| XENON PHARMACEUTICALS INC | 36 | Q3 2023 | 4.7% |
| PIERIS PHARMACEUTICALS INC | 30 | Q3 2023 | 2.8% |
| CYTOKINETICS INC | 29 | Q4 2020 | 11.8% |
| INFINITY PHARMACEUTICALS INC | 29 | Q2 2023 | 4.3% |
| XOMA CORP DEL | 28 | Q3 2023 | 7.3% |
| ARQULE INC | 27 | Q4 2019 | 4.8% |
| CHEMOCENTRYX INC | 26 | Q3 2019 | 13.8% |
| CYTOMX THERAPEUTICS INC | 26 | Q3 2023 | 5.3% |
| CORVUS PHARMACEUTICALS INC | 26 | Q3 2023 | 2.3% |
| ARRAY BIOPHARMA INC | 25 | Q2 2019 | 14.5% |
View BVF INC/IL's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 4 | 2024-01-29 |
| 3 | 2024-01-26 |
| 4 | 2024-01-09 |
| 4 | 2023-12-20 |
| 4 | 2023-11-17 |
| 13F-HR | 2023-11-14 |
| 3 | 2023-11-13 |
| 3 | 2023-11-06 |
| 4 | 2023-11-06 |
View BVF INC/IL's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.